14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
MBIO vs CLYM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas CLYM carries 45.7/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MBIO vs CLYM. Trailing 12-month operating profitability (MBIO 0.0% vs CLYM 0.0%) and valuation multiples (MBIO N/M vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $608.5M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ MBIO vs CLYM Key Questions & Quantitative Answers
As of Nov 16, 2026, Climb Bio, Inc. (CLYM) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 4–1 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MBIO carries a Unified Composite Score of 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin), whereas CLYM carries 45.7/100 (HOLD) at $9.94 (N/M Forward P/E, 0.0% operating margin). Technically, MBIO sits in a Neutral phase (RSI 45.4, UNCLASSIFIED options structure) and CLYM sits in a Neutral phase (RSI 45.2, UNCLASSIFIED options structure).
CLYM leads the Growth & Scale pillar: MBIO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CLYM at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MBIO generates N/A in USD-normalized revenue versus N/A for CLYM. In operating R&D and SG&A reinvestment, MBIO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CLYM.
MBIO and CLYM trade at balanced relative valuation multiples. MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CLYM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MBIO (-43.1% ROE) versus CLYM (-29.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 86% Vol realized risk). By comparison, CLYM carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.50β · 114% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.